Mumbai-based pharmaceutical company Themis Medicare’s anti-viral drug Viralex has received Drugs Controller General of India’s (DCGI) approval, the company informed the stock exchange on Monday.

The company in a statement has said that the drug helps in early relief of clinical symptoms in mild-to-moderate COVID-19 patients.

“As per the results of Phase 3 Randomized, Double-blind, Placebo-controlled Trial, 80.17% of patients treated with Viralex showed clinical improvement on day 6, which is significantly higher (p0.001) from that in the controlled group & (52.38%) among the mild to moderate non-hospitalized COVID-19 patients,” the company said in its press release.

India saw a rise of 1,549 new corona virus infection, taking the infection tally to 4,30,09,390, while the active cases have further declined to 25,106, the Union health ministry said on Monday. The COVID-19 death toll has climbed to 5,16,510 with 31 daily fatalities, the ministry data updated at 8 am stated.